Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.
New anti-obesity drugs should meet a minimum level of weight loss to be considered for approval, the FDA said ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...
Face2FaceAfrica on MSN3h
Women who became ‘family’ after bonding over weight loss drugs share tough truth about weight lossSoon after beginning to use weight loss drugs, Latisha Doty and Alison Bocking met through a TikTok GLP-1 group in 2022, and they have since found strength in each other as they deal with their weight ...
The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new ...
Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...
Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback